| pubmed-article:21171821 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C1655731 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0019652 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0598864 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C1541478 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C1831850 | lld:lifeskim |
| pubmed-article:21171821 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:21171821 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21171821 | pubmed:dateCreated | 2011-4-15 | lld:pubmed |
| pubmed-article:21171821 | pubmed:abstractText | Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous, leading to the potential for tumor escape despite MAGE-A3-induced immunity. We hypothesized that a combination of the hypomethylating agent 5-azacitidine (5AC) and the histone deacetylase inhibitor (HDACi) MGCD0103 (MGC) could induce MAGE-A3 expression in MAGE-A3-negative MM, resulting in recognition and killing of MM cells by MAGE-A3-specific cytotoxic T lymphocytes (CTL). | lld:pubmed |
| pubmed-article:21171821 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21171821 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21171821 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21171821 | pubmed:month | May | lld:pubmed |
| pubmed-article:21171821 | pubmed:issn | 1477-2566 | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:PrenticeH... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:BarlogieBartB | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:ShaughnessyJo... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:StoneKatieK | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:GargTarunT | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:SzmaniaSusann... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:SzymonifkaJac... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:Moreno-BostAm... | lld:pubmed |
| pubmed-article:21171821 | pubmed:author | pubmed-author:HoerringAntje... | lld:pubmed |
| pubmed-article:21171821 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21171821 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:21171821 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21171821 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21171821 | pubmed:pagination | 618-28 | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:meshHeading | pubmed-meshheading:21171821... | lld:pubmed |
| pubmed-article:21171821 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21171821 | pubmed:articleTitle | Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. | lld:pubmed |
| pubmed-article:21171821 | pubmed:affiliation | Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. | lld:pubmed |
| pubmed-article:21171821 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21171821 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21171821 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21171821 | lld:pubmed |
